MAP2K7 and Hyperkeratosis: Analysis revealed that therapy with BRAF and MEK inhibitors was associated with lower risk of all-grade hyperkeratosis than BRAF inhibitor alone, with 8.13% of patients from the BRAF and MEK inhibitors therapy group developing hyperkeratosis compared with 29.83% of the BRAF inhibitor alone group.